liothyronine sodium
liothyronine sodium is listed in the FDA National Drug Code directory with 10 NDC codes, marketed under brand names including Cytomel, liothyronine sodium, Liothyronine Sodium. Available dosage form: tablet.
Drug Details
- Generic Name
- liothyronine sodium
- Brand Names
- Cytomel, liothyronine sodium, Liothyronine Sodium
- Application Number
- NDA010379
- Sponsor
- Pfizer Laboratories Div Pfizer Inc
- NDC Codes
- 10
- Dosage Forms
- TABLET
- Routes
- ORAL
- Active Ingredients
- LIOTHYRONINE SODIUM
Indications and Usage
1 INDICATIONS AND USAGE Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 ) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. (1) - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. (1) 1.1 Hypothyroidism Liothyronine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. 1.2 Pituitary Thyroid-Stimulating Hormone (TSH) Suppression Liothyronine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer . 1.3 Thyroid Suppression Test Liothyronine sodium tablets are indicated as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Limitations of Use Liothyronine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with liothyronine sodium may induce hyperthyroidism [see Warnings and Precautions ( 5.4 )] . Liothyronine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.